Back to Search
Start Over
LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829).
- Source :
-
Annals of Oncology . Nov2022 Suppl 9, Vol. 33, pS1560-S1560. 1p. - Publication Year :
- 2022
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 160398250
- Full Text :
- https://doi.org/10.1016/j.annonc.2022.10.349